Trial · NCT00433745
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
NCT00433745, Phase 2, Completed, National Heart, Lung, and Blood Institute (NHLBI); results first posted 2014-07-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy. Trials, record NCT00433745. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00433745
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
- NCT number
- NCT00433745
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)
- Interventions
- WT1 Peptide Vaccine
- First posted
- 2007-02-12
- Last updated
- 2014-07-08
- Results first posted
- 2014-07-08
- Limitations and caveats
- Although there was one partial response at 7 weeks, this patient went on to relapse as well.~Consequently, all 4 patients had rapid relapses despite vaccination. Accrual was stopped at 4.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cellular Immune Response | 7 weeks after last dose of vaccine | Minimum criterion for a cellular immune response was defined as the emergence of detectable T cell frequency against Willm's tumor 1 (WT1) when the pre-study analysis found no response, or a twofold increase in T cell frequency at any post vaccination time point |
| Secondary | Disease Response | 7 weeks after last dose of vaccine | Clinical response of underlying malignancy to the vaccination |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cellular Immune Response | 7 weeks after last dose of vaccine | participants | NUMBER | |
| SECONDARY | Disease Response | 7 weeks after last dose of vaccine | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cellular Immune Response | WT1 Peptide Vaccine | 4 | participants | ||
| Disease Response | WT1 Peptide Vaccine | Complete response | 0 | participants | |
| Disease Response | WT1 Peptide Vaccine | Partial response | 1 | participants | |
| Disease Response | WT1 Peptide Vaccine | No response | 3 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | WT1 Peptide Vaccine | 4 | |
| Overall Study | COMPLETED | WT1 Peptide Vaccine | 4 | |
| Overall Study | NOT COMPLETED | WT1 Peptide Vaccine | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | WT1 Peptide Vaccine | ||
| Total, other adverse events | WT1 Peptide Vaccine | 0 | 4 |
| Total, serious adverse events | WT1 Peptide Vaccine | 0 | 4 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00433745
GET https://conductscience.org/api/trials/v1/NCT00433745/registered